The HHS issues more details on President Donald Trump's plans to lower U.S. drug prices through most-favored-nation drug ...

Investors and consultants in the space said that they have seen rising enthusiasm among investors as recent funding rounds outpace prior hauls.

The FDA and NIH recently announced plans to phase out animal testing requirements for some therapies. While organoid and AI ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

Lantern Pharma's Q1 2025 earnings reveal clinical progress, AI commercialization plans, and financial discipline.

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.

We recently published a list of the 10 Most Popular AI Stocks to Avoid Now. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.

GE HealthCare (Nasdaq: GEHC) today announced the launch of its CleaRecon DL technology for enhancing CBCT imaging.

AI adoption in pharma can be slow, but failing to scale these new tools across your organization is a missed opportunity.

Tech companies are focusing on AI products over research, say industry experts, who are sounding the alarm about safety.